Nexstim Plc_Company Announcement_Liputusilmoitus_17062024_FINAL_EN
Beskrivning
| Land | Finland |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Company announcement, Helsinki, 17 June 2024 at 12:45 PM (EEST)
Nexstim Plc: Disclosure of Major Holdings according to Chapter 9, Section 10 of the Finnish Securities Markets Act
Nexstim Plc (NXTMH:HEX) (”Nexstim” or ”Company”) has received a notification pursuant to chapter 9, section 5 of the Securities Market Act from Leena Niemistö on 17 June 2024.
The notification is based on the amendment to the Securities Market Act effective April 19, 2024, requiring shareholders to notify the target company and the Financial Supervisory Authority of their ownership and voting shares no later than two months after the enactment of this law if the shareholder's stake in the target company is at least five percent at the time the law takes effect and such share has not been previously disclosed.
Total position of person subject to the notification obligation:
| % of shares and voting rights (total of 7.A) | % of shares and voting rights through financial instruments (total of 7.B) | Total of both in % (7.A + 7.B) | Total number of shares and voting rights of issuer | |
| Resulting situation on the date on which threshold was crossed or reached | 15.37515* | 0.296218** | 13.13344*** | 8,103,096 |
| Positions of previous notification (if applicable) |
Notified details of the resulting situation on the date on which the threshold was crossed:
A: Shares and voting rights
| Class/type of shares ISIN code (if possible) | Number of shares and voting rights | % of shares and voting rights | ||
| Direct (SMA 9:5) | Indirect (SMA 9:6 ja 9:7) | Direct (SMA 9:5) | Indirect (SMA 9:6 ja 9:7) | |
| FI4000506811 | 17,799 | 1,022,416 | 0.263082 | 15.11206 |
| SUBTOTAL A | 1,040,215 | 15.37515 | ||
B: Financial instruments according to SMA 9:6a
| Type of financial instrument | Expiration date | Exercise / Conversion Period | Physical or cash settlement | Number of shares and voting rights | % of shares and voting rights |
| Stock options 2023H | 15.12.2029 | 12,000 | 0.14809 | ||
| Stock options 2024H | 15.12.2030 | 12,000 | 0.14809 | ||
| SUBTOTAL B | 24,000 | 0.29618 |
Information in relation to the person subject to the notification obligation:
Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity:
| Name | % of shares and voting rights | % of shares and voting rights through financial instruments | Total of shares, voting rights, and financial instruments |
| Leena Niemistö | 0.263082 | 0.29618 | 41,799 |
| Kaikarhenni Oy | 15.11206 | 0 | 1,022,416 |
Additional information:
Leena Niemistö holds 55% of Kaikarhenni Oy. First disclosure of holdings regarding the Securities Market Act effective April 19, 2024.
*percentage of shares and voting rights calculated based on total number of shares, 6,765,562.
** percentage of shares and voting rights calculated based on diluted total number of shares, 8,103,096.
*** total percentage of shares (7.A + 7.B) calculated based on diluted total number of shares, 8,103,096.
Further information is available on the website www.nexstim.com, or by contacting:
Mikko Karvinen, CEO
+358 50 326 4101
mikko.karvinen@nexstim.com
The Company’s Certified Advisor is Carnegie Investment Bank AB (publ).
About Nexstim Plc
Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.
Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.
Nexstim’s Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS System 5 is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.
Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBS 6 system is CE marked for the treatment of major depression and chronic neuropathic pain.
Nexstim shares are listed on Nasdaq First North Growth Market Finland.
For more information, please visit www.nexstim.com